NKARTA INC (NKTX) Stock Price, Quote, News and Overview
NASDAQ:NKTX - Nasdaq - US65487U1088 - Common Stock - Currency: USD
NKTX Quote, Performance and Key Statistics
1.85
+0.04 (+2.21%)
The current stock price of NKTX is 1.85 USD. In the past month the price increased by 23.33%. In the past year, price decreased by -73.07%.
NKTX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.81 | 301.01B | ||
| AMGN | AMGEN INC | 13.81 | 147.14B | ||
| GILD | GILEAD SCIENCES INC | 22.63 | 130.06B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1646.62 | 122.76B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.3 | 61.38B | ||
| ARGX | ARGENX SE - ADR | 320.27 | 36.37B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 30.28B | ||
| ONC | BEIGENE LTD-ADR | N/A | 24.70B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.47B | ||
| NTRA | NATERA INC | N/A | 19.23B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.60B | ||
| BIIB | BIOGEN INC | 7.07 | 17.05B |
Related stock screener links
About NKTX
Company Profile
Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California and currently employs 159 full-time employees. The company went IPO on 2020-07-10. The company is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. Both product candidates enable an on-demand, off-the-shelf approach involving scaled manufacturing to broaden patient access. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies. Its NKX019 oncology program is based on the potential to treat a variety of B-cell malignancies by targeting the CD19 antigen that is reliably expressed on these types of cancerous cells. Its NKX101 program is designed to enhance the power of innate NK cell biology to detect and kill cancerous cells.
Company Info
NKARTA INC
1150 Veterans Boulevard
South San Francisco CALIFORNIA 94080 US
CEO: Paul J. Hastings
Employees: 150
Company Website: https://www.nkartatx.com/
Investor Relations: https://ir.nkartatx.com/
Phone: 19254071049
NKARTA INC / NKTX FAQ
What is the stock price of NKARTA INC today?
The current stock price of NKTX is 1.85 USD. The price increased by 2.21% in the last trading session.
What is the ticker symbol for NKARTA INC stock?
The exchange symbol of NKARTA INC is NKTX and it is listed on the Nasdaq exchange.
On which exchange is NKTX stock listed?
NKTX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for NKARTA INC stock?
14 analysts have analysed NKTX and the average price target is 14.11 USD. This implies a price increase of 662.7% is expected in the next year compared to the current price of 1.85. Check the NKARTA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is NKARTA INC worth?
NKARTA INC (NKTX) has a market capitalization of 131.28M USD. This makes NKTX a Micro Cap stock.
How many employees does NKARTA INC have?
NKARTA INC (NKTX) currently has 150 employees.
What are the support and resistance levels for NKARTA INC (NKTX) stock?
NKARTA INC (NKTX) has a support level at 1.84 and a resistance level at 2.01. Check the full technical report for a detailed analysis of NKTX support and resistance levels.
Should I buy NKARTA INC (NKTX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of NKTX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of NKTX, evaluating the profitability, health, valuation and growth aspects
- NKARTA INC (NKTX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- NKARTA INC (NKTX) Sales and EPS estimates to see what analysts future expectations are.
- NKARTA INC (NKTX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- NKARTA INC (NKTX) Insider and Institutional Ownership to learn about the owners and their transactions.
- NKARTA INC (NKTX) Stock Chart to make your own analysis
- NKARTA INC (NKTX) Latest news and press-releases to stay up to date.
Does NKARTA INC (NKTX) stock pay dividends?
NKTX does not pay a dividend.
When does NKARTA INC (NKTX) report earnings?
NKARTA INC (NKTX) will report earnings on 2025-05-08, after the market close.
What is the Price/Earnings (PE) ratio of NKARTA INC (NKTX)?
NKARTA INC (NKTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.66).
What is the Short Interest ratio of NKARTA INC (NKTX) stock?
The outstanding short interest for NKARTA INC (NKTX) is 15.01% of its float. Check the ownership tab for more information on the NKTX short interest.
NKTX Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to NKTX. When comparing the yearly performance of all stocks, NKTX is a bad performer in the overall market: 91.33% of all stocks are doing better.
NKTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to NKTX. No worries on liquidiy or solvency for NKTX as it has an excellent financial health rating, but there are worries on the profitability.
NKTX Financial Highlights
Over the last trailing twelve months NKTX reported a non-GAAP Earnings per Share(EPS) of -1.66. The EPS increased by 28.45% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -21.71% | ||
| ROE | -26.67% | ||
| Debt/Equity | 0 |
NKTX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 87% to NKTX. The Buy consensus is the average rating of analysts ratings from 14 analysts.